Pipeline forecasting: a case study playbook for healthcare and life sciences in the Nordics
The anatomy of a pipeline forecasting engagement that worked — what we tried, what we killed, and what we would repeat. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Nordics.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Nordics. In this market, Nordic buyers reward directness, small buying committees, and a track record over a pitch, so the way you install pipeline forecasting has to be shaped to that reality from day one.
Names removed, numbers preserved. This is a real pipeline forecasting engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.
Week one: diagnosis. The stated problem was "not enough leads". The actual problem was coverage ratios that reward pipeline theatre, which had been masked by inbound velocity that peaked two quarters earlier.
Weeks two to three: rebuild the target list from scratch and re-cut the trigger. Pipeline forecasting works when capital allocation depends on believing the number; the client had drifted away from that first principle.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Nordics it is compounded by the fact that reputation compounding, not campaign spend is what actually gates growth. Pipeline forecasting is only useful here when it is pointed at both constraints at once.
Weeks four to six: live at 20% of previous volume, quality bar raised. Forecast variance vs actuals per quarter moved every week, though absolute numbers stayed modest.
Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.
What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.
The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.
Concretely for healthcare and life sciences in the Nordics: the healthcare teams that install this get past procurement instead of dying in it, and the Nordic teams that install this compound reputation faster than any paid channel could. That is the reason it is worth installing pipeline forecasting deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
RevOps · healthcare · Nordics — answered
- Does pipeline forecasting work for healthcare and life sciences in the Nordics?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Nordics, Nordic buyers reward directness, small buying committees, and a track record over a pitch. The healthcare teams that install this get past procurement instead of dying in it.
- How long until the case study company saw results?
- The metric moved in week four; the absolute number caught up around week ten.
- What did the client stop doing?
- Running old tools on autopilot and confusing volume with progress.
- What did the client keep doing?
- The Monday plan, the Friday review, and the weekly forecast variance vs actuals per quarter readout.
- Is this case study repeatable?
- The process is repeatable; the numbers depend on category, team, and starting point.
- What is the Nordics-specific pitfall when running pipeline forecasting for healthcare?
- Importing a playbook that was built for another market. In the Nordics, Nordic buyers reward directness, small buying committees, and a track record over a pitch — the install has to reflect that.
Growth Broker editorial
Filed under revops · healthcare · nordics